WAT
WATERS CORP /DE/
NYSE · Healthcare · Medical - Diagnostics & Research · US
$434.27
−0.61%Year over year
Reported trailing growth
- Revenue
- +52.5%
- EBITDA
- -10.1%
- EBIT
- -56.2%
- EPS
- -63.9%
- Free cash flow
- -35.7%
- Operating cash flow
- -26.2%
Forward estimates
Based on analyst estimates
- Revenue
- +50.3%
- EBITDA
- +221.1%
- EPS
- +297.8%
Three-year CAGR
- Revenue
- +2.1%
- EBITDA
- -0.2%
- EBIT
- +0.8%
- Net income
- -3.2%
- EPS
- -2.9%
- Free cash flow
- +8.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026